There are currently 1897 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Unconscious Reduction of Fear Through Decoded Neuro-reinforcement
NCT06420557
Recruiting
This application investigates the efficacy of a novel method of neuro-reinforcement based on decoded fMRI activity to reduce fear responses in individuals with phobias (e.g., spiders, snakes). This method works unconsciously in the brain, without the need for participants to endure repeated conscious exposures to their feared stimuli. Fear-related disorders such as specific phobia, post-traumatic stress disorder (PTSD), and other anxiety disorders present a major challenge, as effective treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/28/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Phobia
Register for Updates
Device Use Reimagined Through Education And Mentorship
NCT06546930
Recruiting
Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of youth with T1D in California, use these devices less often and have less optimal glucose control compared to White youth. In phase 1 of this project, we worked directly with Latinx youth, their familie... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
10/28/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
NCT06526884
Recruiting
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher qualit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California
Conditions: Pneumonia, Syncope, Congestive Heart Failure, Cellulitis, Pyelonephritis, AKI - Acute Kidney Injury, Diabetic Foot Infection, Osteomyelitis
Register for Updates
Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
NCT02461446
Recruiting
The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.
Gender:
ALL
Ages:
18 months and above
Trial Updated:
10/24/2024
Locations: University of California at Los Angeles, Los Angeles, California
Conditions: PTEN, ASD, Autism, Macrocephaly, PTEN Hamartoma Tumor Syndrome
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Los Angeles Hematology Oncology Medical Group, Los Angeles, California
Conditions: Multiple Myeloma
Register for Updates
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119
Recruiting
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
10/23/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Register for Updates
A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF
NCT04907825
Recruiting
This is a prospective, open-label, cluster-randomized controlled trial of 400 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) from a total of 40 retail and outpatient community pharmacies. Participants will be randomized (by pharmacy) to either to an intervention arm of pharmacist-led OAC management versus an enhanced usual care arm, wherein physicians receive notification of 'actionable' AF and patients are advised to schedule a physic... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
10/23/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Atrial Fibrillation, Stroke
Register for Updates
Efficacy of a Multi-level School Intervention for LGBTQ Youth
NCT05541406
Recruiting
Efficacy of a Multi-level School Intervention for LGBTQ Youth
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
10/23/2024
Locations: Animo Pat Brown Charter High School, Los Angeles, California +4 locations
Conditions: Depression, Anxiety, Post Traumatic Stress Disorder, Coping Behavior, Sexual Minority Stress, Suicidality, Substance Use, Bullying, Harassment
Register for Updates
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890
Recruiting
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
Register for Updates
Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity
NCT06542835
Recruiting
Non-randomized, two-arm stepped-wedge trial of a multi-level colorectal cancer screening intervention.
Gender:
ALL
Ages:
Between 45 years and 64 years
Trial Updated:
10/21/2024
Locations: AltaMed Health Services Corporation, Los Angeles, California
Conditions: Colorectal Cancer
Register for Updates
Early vs. Late Time-Restricted Eating in Adolescents With Obesity (EL TREA)
NCT05740254
Recruiting
Determine the effectiveness of how limiting the time you eat within an early or late eating window and fasting for remainder of the day will impact weight loss and body mass index (BMI).
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
10/19/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Pediatric Obesity, Time Restricted Feeding, Time Restricted Eating
Register for Updates
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Colorectal Cancer
Register for Updates